ALDX - Aldeyra Therapeutics, Inc.

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5148.72M
Enterprise Value 3107.9M
Trailing P/E N/A
Forward P/E 1-2.73
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)N/A
Price/Book (mrq)1.86
Enterprise Value/Revenue 3N/A
Enterprise Value/EBITDA 6-2.57

Trading Information

Stock Price History

Beta (3Y Monthly) 1.05
52-Week Change 3-31.93%
S&P500 52-Week Change 36.42%
52 Week High 316.70
52 Week Low 34.99
50-Day Moving Average 36.45
200-Day Moving Average 37.82

Share Statistics

Avg Vol (3 month) 3256.06k
Avg Vol (10 day) 3162.69k
Shares Outstanding 520.11M
Float 20.55M
% Held by Insiders 11.94%
% Held by Institutions 173.18%
Shares Short (Jun 28, 2019) 41.29M
Short Ratio (Jun 28, 2019) 43.3
Short % of Float (Jun 28, 2019) 45.79%
Short % of Shares Outstanding (Jun 28, 2019) 44.71%
Shares Short (prior month May 31, 2019) 41.16M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Mar 31, 2019

Profitability

Profit Margin 0.00%
Operating Margin (ttm)0.00%

Management Effectiveness

Return on Assets (ttm)-40.77%
Return on Equity (ttm)-80.57%

Income Statement

Revenue (ttm)N/A
Revenue Per Share (ttm)N/A
Quarterly Revenue Growth (yoy)N/A
Gross Profit (ttm)N/A
EBITDA -41.96M
Net Income Avi to Common (ttm)-46.12M
Diluted EPS (ttm)-1.95
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)43.12M
Total Cash Per Share (mrq)1.57
Total Debt (mrq)377.92k
Total Debt/Equity (mrq)0.48
Current Ratio (mrq)9.17
Book Value Per Share (mrq)2.92

Cash Flow Statement

Operating Cash Flow (ttm)-34.53M
Levered Free Cash Flow (ttm)-57.55M